By clicking on the “Submit” button below, you acknowledge that you have read, understand, and agree to be bound by the terms of the QxMD Online Calculator End User Agreement.
Use this calculator to determine prognosis in Mantle Cell Lymphoma using the Mantle Cell Lymphoma International Prognostic Index (MIPI).
When the cell proliferation index (Ki-67) is not available:
When the cell proliferation index (Ki-67) is available
*ECOG: Eastern Cooperative Oncology Group scale, in which 0 indicates that the patient has no symptoms, 1 indicates that the patient has symptoms but is ambulatory, 2 indicates that the patient is bedridden less than half the day, 3 indicates that the patient is bedridden half the day or longer, and 4 indicates the patient is chronically bedridden and requires assistance with the activities of daily living.
About this calculator
The Mantle Cell Lymphoma International Prognostic Index (MIPI) was derived from a data set of 455 advanced stage MCL patients treated in series of clinical trials in Germany, Europe. Of the evaluable population, approximately 18% were treated with high-dose therapy and stem cell transplantation in first remission. The MIPI is able to classify patients into three risk groups: low risk (median survival not reached after median 32 months follow-up and 5-year OS rate of 60%), intermediate risk (median survival 51 months) and high risk (median survival 29 months). In addition to the 4 independent prognostic factors included in the model, the cell proliferation index (Ki-67) was also shown to have additional prognostic relevance. When the Ki67 is available, a biologic MIPI (MIPIb) can be calculated. Risk group is assigned based on MIPI score prior to rounding.
The MIPI was proposed and validated by Hoster et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558-565. (2008)
QxMD Hematology contributing author: Dr. Matthew Cheung, MD, SM, FRCP(C)